News
Raising doubts about vaccines In a Senate health committee hearing last week, Kennedy wrongly claimed that the only vaccines ...
Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...
Health-care companies rose as some beaten-down stocks recouped some of their losses. UnitedHealth Group rose by more than 7%, but remain more than one-third lower for the year to date. Similarly, ...
The vaccine, Nuvaxovid, is the third coronavirus shot to gain full approval, joining vaccines from Pfizer and Moderna. It has ...
The FDA has approved Novavax’s protein-based COVID-19 vaccine, giving some Americans another option besides messenger RNA vaccines to prevent SARS-CoV-2 infection.
The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax's COVID-19 vaccine, but only for certain ...
Explore more
The FDA has approved Novavax’s COVID-19 vaccine, Nuvavoxid, for use in adults 65 and older and in individuals ages 12-64 who have at least one underlying health condition. The approval is based on ...
The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.
While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...
Tesla's Chinese rival Xiaomi announced its electric SUV set to compete with Tesla's Model Y will be launched Thursday. TXNM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results